Oncology Corporate Profile
Aptose Biosciences is a clinical-stage oncology company pioneering targeted therapies and companion diagnostics that offer a new approach to inducing apoptosis (programmed cell death) and personalized treatment strategies for patients with life-threatening cancers.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|APTO-253||KLF4 activator||Acute Myelogenous Leukemia (AML)||I|
|APTO-253||KLF4 activator||Various cancer types||I|
|APTO-500||MEK inhibitor||Various cancer types||Preclinical||Genentech / Roche|
|IL-17E||immunomodulator||Various cancer types||Preclinical|
View additional information on product candidates here »